NexTel Medical Corp f/k/a Exousia Pro, Inc. (OTCPK: MAJI), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems, is proud to announce the commencement of the first critical phase in bringing its revolutionary cancer screening test to the global market.

NexTel will begin the distribution of test kits this week to initiate the collection of essential control samples. These samples serve as the foundational benchmark for validation against 100 dedicated test samples. While the initial patent was granted based on a limited sample set, NexTel is now aggressively expanding its testing protocols to include a broader range of cancer types. This scaling of sample size and diversity is a vital step in confirming the universal efficacy of the test as the company moves toward full-scale commercialization.

A New Frontier in Early Detection: The NANOG DNA Advantage

The core of NexTel’s diagnostic portfolio is the proprietary NANOG DNA cancer screening test. Designed as a non-invasive, high-precision tool, the test is engineered to detect a wide spectrum of malignancies, including the "silent killers"—highly aggressive cancers that are notoriously difficult to identify until they reach advanced stages.

The NANOG DNA assay offers a transformative shift in the liquid biopsy landscape:

• Universal Multi-Cancer Screening: A single, comprehensive tool designed to identify various cancer types simultaneously, removing the need for multiple, invasive procedures.
• Unrivaled Sensitivity: By measuring Exosomal NANOG DNA, a potent and reliable biomarker, the test remains unaffected by external medications or co-existing health conditions.
• Seamless Integration: Requiring only a 2 ml saliva sample, the test utilizes standard PCR processing. This enables rapid, scalable results and removes the traditional barriers to cost and time associated with early detection.
  
  

Executive Commentary

“This milestone represents an incredibly exciting leap forward in our mission to democratize cancer screening,” said Matt Dwyer, President of NexTel Medical Corp. “Cancer is a diagnosis that has touched every one of us. We know that early detection is the absolute key to survival, yet the current hurdles of cost and accessibility keep far too many people from getting the answers they need.   Our goal is to offer an affordable solution so simple and accessible that it changes the diagnostic landscape forever. This test is so efficient that a participant could purchase the kit, walk to their car, and complete the screening before they even buckle their seatbelt. We are thrilled to be this much closer to putting that power in the hands of the public.”